Drug Insight: Breast cancer prevention and tissue-targeted hormone replacement therapy

Nature Clinical Practice Endocrinology and Metabolism

Volumn 3, Issue 8, 2007, Pages 584-593

  Labrie, Fernand ^a,b  

^a UNIVERSITÉ LAVAL   (Canada)

^b LAVAL UNIVERSITY   (Canada)

Author keywords

Breast cancer; Dehydroepiandrosterone; Selective estrogen receptor modulators; Tissue targeted hormone replacement therapy

Indexed keywords

ACOLBIFENE; ANABOLIC AGENT; ANASTROZOLE; ANDROGEN; AROMATASE INHIBITOR; ARZOXIFENE; BAZEDOXIFENE; BISPHOSPHONIC ACID DERIVATIVE; CALUSTERONE; CHOLESTEROL; FULVESTRANT; GLUCOSE; LASOFOXIFENE; LETROZOLE; PRASTERONE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SEX HORMONE; TAMOXIFEN; TESTOSTERONE; TRIACYLGLYCEROL;

BREAST CANCER; CANCER HORMONE THERAPY; CANCER RISK; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DRUG EFFICACY; DRUG INDICATION; DRUG SPECIFICITY; DRUG TOLERABILITY; DRUG TOLERANCE; DRUG TREATMENT FAILURE; ENDOMETRIUM CANCER; ESTROGEN ACTIVITY; FRACTURE; FRAGILITY FRACTURE; GENE EXPRESSION PROFILING; GLUCOSE METABOLISM; HORMONE SUBSTITUTION; HOT FLUSH; HUMAN; METASTASIS; NONHUMAN; OSSIFICATION; OSTEOPOROSIS; PREMENOPAUSE; PRIORITY JOURNAL; REVIEW; STEROIDOGENESIS; THROMBOEMBOLISM; TISSUE SPECIFICITY; TREATMENT DURATION; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; UTERUS CANCER; VERTEBRA FRACTURE;

AROMATASE INHIBITORS; BREAST NEOPLASMS; DEHYDROEPIANDROSTERONE; ESTROGEN ANTAGONISTS; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN; UTERINE NEOPLASMS;

EID: 34447623585     PISSN: 17458366     EISSN: 17458374     Source Type: Journal    
DOI: 10.1038/ncpendmet0559     Document Type: Review

References (55)

1. Jemal A et al. (2007) Cancer statistics, 2007. CA Cancer J Clin 57: 43-66
2. Berry DA et al. (2005) Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 353: 1784-1792
3. Fisher B et al. (1996) Five versus more than five years of tamoxifen for breast cancer patients with negative lymph nodes and estrogen positive tumors. J Natl Cancer Inst 88: 1529-1542
4. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365: 1687-1717
5. Women's Health Initiative (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 288: 321-333
6. Beral V et al. (2005) Endometrial cancer and hormone-replacement therapy in the Million Women Study. Lancet 365: 1543-1551
7. Archer DF et al. (1999) A randomized comparison of continuous combined transdermal delivery of estradiol-norethindrone acetate and estradiol alone for menopause. CombiPatch Study Group. Obstet Gynecol 94: 498-503
8. Labrie F et al. (2001) EM-652 (SCH 57068), a pure SERM having complete antiestrogenic activity in the mammary gland and endometrium. J Steroid Biochem Mol Biol 79: 213-225
9. Vogel VG et al. (2006) Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 295: 2727-2741
10. Barrett-Connor E et al. (2006) Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 355: 125-137
11. Melnikow J et al. (2006) Chemoprevention: drug pricing and mortality: the case of tamoxifen. Cancer 107: 950-958
12. Vogel VG et al. (2002) Re: tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 94: 1504
13. Land SR et al. (2006) Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 295: 2742-2751
14. Paridaens R et al. (2003) Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer. Ann Oncol 14: 1391-1398
15. Coombes RC et al. (2004) A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350: 1081-1092
16. Poulin R and Labrie F (1986) Stimulation of cell proliferation and estrogenic response by adrenal C19-?5-steroids in the ZR-75-1 human breast cancer cell line. Cancer Res 46: 4933-4937
17. Howell A et al. (2005) Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365: 60-62
18. Howell A et al. (2004) Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial. J Clin Oncol 22: 1605-1613
19. Howell A et al. (2002) Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progression after prior endocrine treatment. J Clin Oncol 20: 3396-3403
20. Johnston SR (2005) Endocrinology and hormone therapy in breast cancer: selective oestrogen receptor modulators and downregulators for breast cancer - have they lost their way? Breast Cancer Res 7: 119-130
21. Roy J et al. (2003) A novel pure SERM achieves complete regression of the majority of human breast cancer tumors in nude mice. Breast Cancer Res Treat 81: 223-229
22. Gutman M et al. (2002) Comparison of the effects of EM-652 (SCH 57068), tamoxifen, toremifene, droloxifene, idoxifene, GW-5638 and raloxifene on the growth of human ZR-75-1 breast tumors in nude mice. Int J Cancer 99: 273-278
23. Gutman M et al. (2003) Effect of treatment sequence with radiotherapy and the antiestrogen EM 800 on the growth of ZR 75 1 human mammary carcinoma in nude mice. Int J Cancer 103: 268-276
24. Simard J et al. (1997) Blockade of the stimulatory effect of estrogens, OH-tamoxifen, OH-toremifene, droloxifene and raloxifene on alkaline phosphatase activity by the antiestrogen EM-800 in human endometrial adenocarcinoma Ishikawa cells. Cancer Res 57: 3494-3497
25. Labrie F et al. (2004) Activity and safety of the orally active pure antiestrogen EM-800 (SCH 57050) in tamoxifen-resistant breast cancer. J Clin Oncol 22: 864-871
26. Duvernoy CS et al. (2005) Vascular events in the multiple outcomes of raloxifene evaluation (MORE) trial: incidence, patient characteristics and effect of raloxifene. Menopause 12: 444-452
27. Labrie F et al. (2005) Is DHEA a hormone? Starling Review. J Endocrinol 187: 169-196
28. Labrie F et al. (2006) Androgen glucuronides, instead of testosterone as the new markers of androgenic activity in women. J Steroid Biochem Mol Biol 99: 182-188
29. Wierman ME et al. (2006) Androgen therapy in women: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 91: 3697-3710
30. Gammon MD and Thompson WD (1991) Polycystic ovaries and the risk of breast cancer. Am J Epidemiol 134: 818-824
31. Dimitrakakis C et al. (2003) A physiologic role for testosterone in limiting estrogenic stimulation of the breast. Menopause 10: 292-298
32. Labrie F et al. (2003) Endocrine and intracrine sources of androgens in women: inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone. Endocr Rev 24: 152-182
33. Ulrich P (1939) Testosterone (male hormone) and its possible role in the treatment of some breast cancers [French]. Acta - Unio Internationalis Contra Cancrum 4: 377-379
34. Sturgeon SR et al. (2004) Serum levels of sex hormones and breast cancer risk in premenopausal women: a case-control study (USA). Cancer Causes Control 15: 45-53
35. Key T et al. (2002) Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst 94: 606-616
36. Beattie MS et al. (2006) Endogenous sex hormones, breast cancer risk, and tamoxifen response: an ancillary study in the NSABP Breast Cancer Prevention Trial (P-1). J Natl Cancer Inst 98: 110-115
37. Onland-Moret NC et al. (2003) Urinary endogenous sex hormone levels and the risk of postmenopausal breast cancer. Br J Cancer 88: 1394-1399
38. Tworoger SS et al. (2006) The association of plasma DHEA and DHEA sulfate with breast cancer risk in predominantly premenopausal women. Cancer Epidemiol Biomarkers Prevent 15: 967-971
39. Tamimi RM et al. (2006) Combined estrogen and testosterone use and risk of breast cancer in postmenopausal women. Arch Intern Med 166: 1483-1489
40. Vermeulen A et al. (1986) Aromatase, 17β-hydroxysteroid dehydrogenase and intratissular sex hormone concentrations in cancerous and normal glandular breast tissue in postmenopausal women. J Steroid Biochem 25: 799-802
41. Bone Health and Osteoporosis: A Report of the Surgeon General [http://www.surgeongeneral.gov/library/bonehealth/] (accessed March 27 2007)
42. Fisher B et al. (1998) Tamoxifen for prevention of breast cancer: report of the national surgical adjuvant breast and bowel project P-1 study. J Natl Cancer Inst 90: 1371-1388
43. Delmas PD et al. (2002) Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J Clin Endocrinol Metab 87: 3609-3617
44. Ettinger B et al. (2004) Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. J Bone Miner Res 19: 745-751
45. Michalska D et al. (2006) The effect of raloxifene after discontinuation of long-term alendronate treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab 91: 870-877
46. Martel C et al. (1998) Predominant androgenic component in the stimulatory effect of dehydroepiandrosterone on bone mineral density in the rat. J Endocrinol 157: 433-442
47. Labrie F et al. (1997) Effect of 12-month DHEA replacement therapy on bone, vagina, and endometrium in postmenopausal women. J Clin Endocrinol Metab 82: 3498-3505
48. Diamond P et al. (1996) Metabolic effects of 12-month percutaneous dehydroepiandrosterone replacement therapy in postmenopausal women. J Endocrinol Suppl 150: S43-S50
49. Villareal DT and Holloszy JO (2004) Effect of DHEA on abdominal fat and insulin action on elderly women and men: a randomized controlled trial. JAMA 292: 2243-2248
50. Morales AJ et al. (1998) The effect of six months treatment with a 100 mg daily dose of dehydroepiandrosterone (DHEA) on circulating sex steroids, body composition and muscle strength in age-advanced men and women. Clin Endocrinol 49: 421-432
51. Jankowski CM et al. (2006) Effects of dehydroepiandrosterone replacement therapy on bone mineral density in older adults: a randomized, controlled trial. J Clin Endocrinol Metab 91: 2986-2993
52. Nair KS et al. (2006) DHEA in elderly women and DHEA or testosterone in elderly men. N Engl J Med 355: 1647-1659
53. Weigelt B et al. (2003) Gene expression profiles of primary breast tumors maintained in distant metastases. Proc Natl Acad Sci USA 100: 15901-15905
54. Labrie F et al. (2003) The combination of a novel SERM with an estrogen protects the mammary gland and uterus in a rodent model: the future of postmenopausal women's health? Endocrinology 144: 4700-4706
55. Stomati M et al. (2000) Six-month oral dehydroepiandrosterone supplementation in early and late postmenopause. Gynecol Endocrinol 14: 342-363